5/26/10. Oren Fix, MD, MSc Transplant Hepatology Division of Gastroenterology University of California San Francisco
|
|
- Elvin Baldwin
- 5 years ago
- Views:
Transcription
1 Oren Fix, MD, MSc Transplant Hepatology Division of Gastroenterology University of California San Francisco Epidemiology Surveillance Biomarkers Biopsy Treatment local regional therapy, systemic chemotherapy, transplant Liver criteria, drop- out, expanded criteria, down- staging >600,000 people worldwide 6 th most common cancer Deaths incidence 3 rd most common cause of cancer- related death Incidence is increasing due to hepa@@s C and non- alcoholic faoy liver disease Parkin et al. CA Cancer J Clin 2005 El- Serag. Gastroenterol
2 reduce mortality or provide meaningful improvement in survival 37% in HCC- related mortality with AFP + ultrasound every 6 months in hepa@@s B in China Cost- effec@ve using Markov modeling Bruix, Sherman. Hepatology 2005 Zhang et al. J Cancer Res Clin Oncol 2004 Hepa11s B carriers Asian males 40 years Asian females 50 years All cirrho@c hepa@@s B carriers Family history of HCC Africans >20 years Pa@ents with high HBV DNA and those with ongoing hepa@c inflammatory ac@vity Non- hepa11s B cirrhosis Hepa@@s C Alcoholic cirrhosis Gene@c hemochromatosis Primary biliary cirrhosis Alpha- 1- an@trypsin deficiency* Non- alcoholic hepa@@s* Autoimmune hepa@@s* *These groups have increased risk of HCC but data are lacking that show benefit with surveillance Bruix, Sherman. Hepatology 2005 Ultrasonography Sensi@vity 65-80%, specificity >90% Operator- dependent, cirrhosis, obesity AFP has poor sensi@vity and specificity 20 ng/ml = 60% sensi@vity 200 ng/ml = 22% sensi@vity PPV of 20 ng/ml = 25% (5% prevalence) PPV of 400 ng/ml = 60% Bruix, Sherman. Hepatology 2005 Trevisani et al. J Hepatol
3 Des- gamma carboxyprothrombin Lens culinaris- of AFP Glypican- 3 Pancrea@@s- associated an@gen P16 methyla@on Human hepatocyte growth factor Cytokera@n- 19 Transforming growth factor beta- 1 Lipoprotein a Erythrocyte binding polyamine Tissue polypep@de specific an@gen C- reac@ve protein P53 an@bodies CD24 gene Telomerase ac@vity Prothymosin alfa Microsatellite DNA analysis HCC- associated gene 1 Epidermal growth factor receptor Marrero. Clin Liver Dis 2005 May be more sensi@ve/specific than AFP for differen@a@ng HCC from chronic liver disease Sensi@vity diminishes with points AFP and DCP complementary but neither are sufficiently accurate for surveillance Marrero et al. Hepatology 2003 Lok et al. Gastroenterol 2010 Diagnosis PPV of AFP >200 ng/ml in a cirrho@c pa@ent with a liver mass is high Prognosis AFP and DCP predict post- transplant recurrence High DCP associated with microvascular invasion and poor differen@a@on Trevisani et al. J Hepatol 2001 Yao et al. Am J Transpl 2005 Fujiki et al. Am J Transpl
4 Different vascular supply of normal liver parenchyma and HCC CT imaging findings arterial phase enhancement Decreased on portal venous phase Similar MR findings T2 hyperintensity Pseudocapsule is Taouli, Krinsky. Liver Transpl 2006 OPTN database analysis 44.1% accuracy compared to pathologic stage Understaging = overstaging 21% of pa@ents given priority for transplant for HCC had no tumor on pathology Accuracy improved in older pa@ents, staging <90 days before transplant, stage >1 Understaging associated with higher risk of recurrence Freeman et al. Liver Transpl 2006 Shah et al. Transplanta@on 2006 Con Most lesions >2 cm can be diagnosed noninvasively 10% risk of false nega@ve diagnosis Accuracy decreases with smaller lesions Risk of progression for small lesions is low Bleeding Needle track seeding: 0-5.1% S@gliano, Burroghs. J Hepatol
5 Pro May allow priority for transplant High false rate of radiologic staging leads to unnecessary transplants Risk of tumor seeding is low and outcome usually not affected Tumor predict recurrence and may help select for transplant Marsh, Dvorchik. J Hepatol 2005 Marshall et al. Liver Transpp 2010 Yao et al. Am J Transpl 2005 Surgical resec@on Local regional therapy (LRT) Percutaneous ethanol abla@on (PEI) Radiofrequency abla@on (RFA) Transcatheter arterial chemoemboliza@on (TACE) and Drug- Elu@ng Beads (DEB) Radioemboliza@on (Y- 90) Systemic chemotherapy Liver transplanta@on Available to 5% of pa@ents Single, small lesion ( 5 cm) No liver disease of Child class A cirrhosis No portal hypertension (normal platelets) Normal bilirubin Rust, Gores. Clin Liver Dis 2001 Llovet et al. Hepatol
6 No difference in recurrence or survival in RCT comparing surgical with PEI No difference in overall survival and disease- free survival for small HCC in RCT comparing surgical and RFA Huang et al. Ann Surg 2005 Chen et al. Ann Surg 2006 Survival benefit demonstrated by several RCTs and meta- analysis China Europe TACE 1- yr: 57% 3- yr: 26% 1- yr: 82% 3- yr: 29% Control 1- yr: 32% 3- yr: 3% 1- yr: 63% 3- yr: 17% Meta- analysis: OR 0.42, 95% CI Lo et al. Hepatology 2002 Llovet et al. Lancet 2002 Llovet et al. Hepatology 2003 Improved 3- year survival in transplant who received LRT compared to no LRT (79% vs 75%, P=.03) UCSF analysis: improved survival with LRT (94% vs 81%, P=.049) review at UPenn: no survival benefit (84% vs 91%, P=.6) Freeman et al. Am J Transpl 2008 Yao et al. Am J Transpl 2005 PorreO Liver Transpl
7 YOrium- 90: pure beta emioer Half life 64 hours Range mm Biodegradable glass microspheres with diameters of μm Can treat with more advanced liver disease and portal vein thrombosis No RCTs Riaz et al. Q J Nucl Med Mol Imaging 2009 Sorafenib Oral mul@kinase inhibitor Blocks tumor cell signal transduc@on, prolifera@on, angiogenesis Approved for unresectable HCC 11/2007 First approved systemic drug for HCC Only medica@on proven to significantly improve overall survival in HCC Llovet et al. NEJM 2008 Median overall survival Sorafenib 10.7 months Placebo 7.9 months HR 0.69, 95% CI , P<.001 No difference in to symptoma@c progression (4.1 vs 4.9 mo) Side effects: diarrhea, weight loss, hand- foot skin syndrome, hypophosphatemia Llovet et al. NEJM
8 HCC considered the clearest 6 of first 7 pa@ents transplanted for hepa@c malignancy Early case series 9/11 (82%) developed recurrence in 1 year Only 1 survived 17 months Incidental HCC in 12 pa@ents: 11 survived 4 months to >15 years without recurrence Starzl et al. Ann Int Med 1966 Iwatsuki et al. Ann Surg 1985 BeOer outcomes in a concurrent series HCCs cm, 12 with mul@ple tumors ranging from 8-15 cm Recurrence in 24/37 (65%) 2- year survival 38% Disappoin@ng yet some pallia@on and a few long- term cures O Grady et al. Ann Surg 1988 German case series of 52 pa@ents Many pa@ents with large tumors >5 cm to 23 cm Tumor invasion of portal vein, extrahepa@c spread Median survival 9 months Median survival 10 yrs in 4 pa@ents with stage II Ringe et al. Ann Surg
9 Mazzaferro et al. NEJM 1996 criteria: Single tumor 5 cm 2-3 tumors, each 3 cm No tumor invasion of blood vessels or lymph nodes 4- year recurrence- free survival 83% 4- year overall survival 75% 1 lesion 5 cm 2 to 3, none >3 cm + Absence of Macroscopic Vascular Invasion Absence of Extra- hepa1c Spread Mazzaferro et al. NEJM 1996 Milan Criteria T1 1 lesion <2 cm T2 1 lesion 2-5 cm 2 or 3 lesions, none >3cm UNOS Policy 3.6 9
10 Urgency for transplant risk of death Urgency for transplant = risk of progression beyond stage II MELD for T1 MELD for T Wiesner et al. Gastroenterol 2004 Freeman et al. Am J Transpl 2008 Inten@on- to- treat analysis of resec@on vs transplanta@on Mean wai1ng 1me 2- year survival days 84% days 54% Llovet et al. Hepatology 1999 Inten@on- to- treat analysis of resec@on vs transplanta@on Mean wai1ng 1me 2- year survival 2- year post- transplant survival days 84% 84% days 54% 80% Difference in survival due to 23% drop- out rate Llovet et al. Hepatology
11 Low drop- out rate <6 months increase thereazer Higher risk of drop- out with tumors >3 cm and presence of 3 tumors of diagnosis or lis@ng Few pa@ents with HCC can be successfully maintained on the wai@ng list beyond 1 year Yao et al. Liver Transpl 2002 Yao et al. Liver Transpl 2003 Uncontrolled trials suggest LRT may reduce risk of drop- out No RCTs of LRT and drop- out Sorafenib? High- risk donors (cab+, HCV) Living donor liver transplanta@on Expanded criteria Down- staging Vitale et al. Hepatology 2010 Yao et al. Liver Transpl 2002 Yao et al. Liver Transpl 2003 Graziadei et al. Liver Transpl 2003 Milan criteria may be too restric@ve Some expansion of criteria demonstrates post- transplant outcomes comparable to Milan criteria UCSF Up- To- 7 Total Tumor Volume Marsh, Schmidt. Liver Transpl 2010 Yao et al. Hepatology 2001 Yao et al. Am J Transpl 2007 Mazzaferro et al. Lancet 2009 Toso et al. Liver Transpl
12 Milan UCSF* 1 lesion 5 cm 6.5 cm 2-3 lesions Each 3 cm Each 4.5 cm No vascular invasion No extrahepa1c spread *Total tumor diameter 8 cm 5- year recurrence- free probabili@es Milan 90.1% UCSF 93.6% Yao et al. Hepatology 2001 Yao et al. Am J Transpl = number of nodules + size (cm) of largest nodule 5- year overall survival: Milan 73.3% Up- to- 7: 71.2% Based on pathologic analysis Mazzaferro et al. Lancet 2009 The further the distance the greater the price Cri@cs: Expansion of criteria will lead to higher drop- out and recurrence rates, unfair to non- HCC pa@ents on wai@ng list Should all selec@on criteria be compared to Milan? Should the goal be a minimum acceptable post- transplant survival? Llovet et al. Sem Liver Dis 2005 Yao. Am J Transpl
13 Response to LRT may be a beoer predictor of recurrence than tumor stage 8 cm Down- staging Transplant? Outcome? Chapman et al. Ann Surg 2008; OOo et al. Liver Transpl 2006 Yao et al. Liver Transpl 2005; Yao et al. Hepatology 2008 Number of Lesions Size of Each Lesion (cm) Total Tumor Diameter (cm) 1 >5 but No vascular invasion on imaging Tumor size and number mee@ng T2 criteria OR Complete tumor necrosis without residual tumor (equivalent to oblitera@on of tumor) AND Minimum follow- up period of 3 months azer down- staging before liver transplanta@on 13
14 N=88 Kaplan- Meier Probabili1es 84.1% 61.3% Follow- up in Years n=50 Kaplan- Meier Probabili1es 97.6% 83.8% Follow- up in Years n=50 Kaplan- Meier Probabili1es 97.8% 95.0% Follow- up in Years 14
15 Pretransplant imaging criteria Organ (MELD) Role of LRT as a bridge to transplant Role of resec@on Expanded criteria Down- staging Pomfret et al. Liver Transpl HCC incidence is increasing, mortality is high, and it is a leading cause of cancer death 2. Surveillance of HCC in at- risk popula@ons improves survival 3. Biomarkers, including AFP, are not sensi@ve or specific to be used alone for surveillance, but have u@lity in diagnosis and prognosis 4. Radiologic imaging may be almost 50% inaccurate leading to both over- and understaging 5. Biopsy of liver masses is ozen unnecessary to establish diagnosis of HCC but may be useful in the future for pa@ent selec@on for transplant 6. LRT improves survival and may reduce drop- out and post- transplant recurrence 15
16 7. Liver is the most therapy for highly selected 8. Even for eligible drop out due to tumor progression limits access to transplant 9. Current transplant criteria for HCC based on tumor staging may be too 10. criteria are evolving and UCSF is at the forefront of the movement to expand criteria and down- stage 11. BeOer predictors of tumor biology and behavior are needed 12. Response to LRT are surrogates for tumor biology that allow of with HCCs with a lower risk of recurrence Management of HCC requires a mul@disciplinary approach that involves all aspects of HCC diagnosis and therapy Early referral to a hepatologist who is part of a mul@disciplinary HCC group is essen@al to improving survival in this otherwise devasta@ng disease 16
Surveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationHCC: Is it an oncological disease? - No
June 13-15, 2013 Berlin, Germany Prof. Oren Shibolet Head of the Liver Unit, Department of Gastroenterology Tel-Aviv Sourasky Medical Center and Tel-Aviv University HCC: Is it an oncological disease? -
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatocellular Carcinoma HCC: Age
More informationPaul Martin MD FACG. University of Miami
Paul Martin MD FACG University of Miami 1 Liver cirrhosis of any cause Chronic C o c hepatitis epat t s B Risk increases with Male gender Age Diabetes Smoking ~5% increase in HCV-related HCC between 1991-28
More information9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES
UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationHepatocellular Carcinoma: Transplantation, Resection or Ablation?
Hepatocellular Carcinoma: Transplantation, Resection or Ablation? Roberto Gedaly MD Chief, Abdominal Transplantation Transplant Service Line University of Kentucky Nothing to disclose Disclosure Objective
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationTumor incidence varies significantly, depending on geographical location.
Hepatocellular carcinoma is the 5 th most common malignancy worldwide with male-to-female ratio 5:1 in Asia 2:1 in the United States Tumor incidence varies significantly, depending on geographical location.
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More informationReconsidering Liver Transplantation for HCC in a Era of Organ shortage
Reconsidering Liver Transplantation for HCC in a Era of Organ shortage Professor Didier Samuel Centre Hépatobiliaire Inserm-Paris Sud Research Unit 1193 Departement Hospitalo Universitaire Hepatinov Hôpital
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C
More informationHCC RADIOLOGIC DIAGNOSIS
UCSF Transplant 2010 THE BEFORE AND AFTER HEPATOCELLULAR CARCINOMA MANAGEMENT Francis Yao, M.D. Professor of Clinical Medicine and Surgery Medical Director, Liver Transplantation University of California,
More informationTreatment of Hepatocellular Carcinoma. Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center
Treatment of Hepatocellular Carcinoma Andrew J. Muir, MD MHS Division of Gastroenterology Duke University Medical Center Epidemiology of HCC: world The 5 th most common cancer worldwide > 500, 000 new
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationOptimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC)
XXVI SETH Congress- 30 November 2017 Optimizing Patient Selection, Organ Allocation, and Outcomes in Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) Neil Mehta, MD University of California,
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationLiver Cancer: Diagnosis and Treatment Options
Liver Cancer: Diagnosis and Treatment Options Fred Poordad, MD Chief, Hepatology University Transplant Center Professor of Medicine UT Health, San Antonio VP, Academic and Clinical Affairs, Texas Liver
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationLearning Objectives. After attending this presentation, participants will be able to:
Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationAre we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?
Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma
More information21/02/2014. Disclosures. HCC: predicting recurrence. Outline. Liver transplant: Beyond Milan?
Disclosures HCC: predicting recurrence Peter Ghali, MD, FRCPC, MSc (epid) None relevant to this talk other than off-label use of sirolimus Toronto, February 2014 Outline Recurrence after what? Locoregional
More informationAdvances in percutaneous ablation for hepatocellular carcinoma
Advances in percutaneous ablation for hepatocellular carcinoma P. Nahon1,2,3 1 Hepatology, Jean Verdier Hospital, APHP, Bondy, France 2 Paris 13 university, Sorbonne Paris Cité, UFRSMBH, Bobigny, France
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationTHE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationHEPATOCELLULAR CARCINOMA: AN OVERVIEW
HEPATOCELLULAR CARCINOMA: AN OVERVIEW John K. Olynyk Head, Department of Gastroenterology & Hepatology Fiona Stanley Fremantle Hospital Group Dean of Research, Edith Cowan University RISING MORTALITY OF
More informationHepatocellular Carcinoma for NNN Cancer Webinar Series
Hepatocellular Carcinoma for NNN Cancer Webinar Series Brian J McMahon, MD Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium * None Disclosures Outline of Talk * Epidemiology of
More informationLiver Transplantation for HCC Which Criteria?
Liver Transplantation for HCC Which Criteria? Jacques Belghiti - François Durand Claire Francoz Hepato-Biliary-Pancreatic Liver Surgery and Liver Transplantation Unit Hôpital Beaujon (AP-HP), Clichy -
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationSerum Markers for Hepatocellular Carcinoma
REVIEW Serum Markers for Hepatocellular Carcinoma Paul Clark, M.B.B.S. (Hons), M.P.H., Ph.D., F.R.A.C.P. Hepatocellular carcinoma (HCC) accounts for a significant and increasing burden of disease globally.
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationScreening for HCCwho,
Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology
More informationRadiofrequency Ablation of Primary or Metastatic Liver Tumors
Radiofrequency Ablation of Primary or Metastatic Liver Tumors Policy Number: 7.01.91 Last Review: 9/2018 Origination: 2/1996 Next Review: 9/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationLatest Developments in the Treatment of Hepatocellular Carcinoma
Latest Developments in the Treatment of Hepatocellular Carcinoma Roniel Cabrera, MD MS Associate Professor of Medicine Director of Hepatology and Medical Director of Liver Transplantation Division of Gastroenterology,
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More informationWaitlist Priority for Hepatocellular Carcinoma Beyond Milan Criteria: A Potentially Appropriate Decision Without a Structured Approach
American Journal of Transplantation 2014; 14: 79 87 Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12530
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Louisville & Louisville VAMC 2010 Magnitude of the Problem 95% of
More informationHepatocellular Carcinoma Recurrence After Liver Transplantation: an Analysis of Risk Factors and Incidence from Oregon Health & Science University
Portland State University PDXScholar University Honors Theses University Honors College 2016 Hepatocellular Carcinoma Recurrence After Liver Transplantation: an Analysis of Risk Factors and Incidence from
More informationHCC: SURVEILLANCE AND MANAGEMENT
HCC: SURVEILLANCE AND MANAGEMENT Hillel Tobias, MD PhD Professor of Medicine and Surgery Medical Director, Liver Transplant Service New York University Langone Medical Center Normal hepatocytes - - - -
More informationLiver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF-Expanded Criteria Based on Preoperative Imaging
American Journal of Transplantation 2007; 7: 2587 2596 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationHCC and mass effect. Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? What you need to know about AFP.
Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? Arun J Sanyal M.B.B.S., M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University Imaging features used
More informationNIH Public Access Author Manuscript J Surg Res. Author manuscript; available in PMC 2011 May 18.
NIH Public Access Author Manuscript Published in final edited form as: J Surg Res. 2011 April ; 166(2): 189 193. doi:10.1016/j.jss.2010.04.036. Hepatocellular Carcinoma Survival in Uninsured and Underinsured
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationDiagnosis and Management of Hepatocellular Carcinoma: 2009 Update
Project ID #09-002-E Release Date: May 30, 2009 Expiration: May 30, 2010 Diagnosis and Management of Hepatocellular Carcinoma: 2009 Update Joseph K. Lim, MD Assistant Professor of Medicine Director, Yale
More informationHepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010
Bronx VA Medical Center Mount Sinai School of Medicine Hepatocellular Carcinoma in HIV-infected Patients A Growing Complication of Coinfection with HCV or HBV Mon, 31 May 2010 Norbert Bräu, MD, MBA Associate
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationHepatocellular Carcinoma: Epidemiology and Screening
Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman
More informationStaging and prognostic systems: beyond BCLC?
Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationUPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA
UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the
More informationExtending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma
LIVER TRANSPLANTATION 13:S48-S54, 27 SUPPLEMENT Extending Indication: Role of Living Donor Liver Transplantation for Hepatocellular Carcinoma Satoru Todo, 1 Hiroyuki Furukawa, 2 Mitsuhiro Tada, 3 and the
More informationHCC su cirrosi: terapia delle forme avanzate con farmaci bersaglio. C è ancora spazio per l ablazione percutanea?
HCC su cirrosi: terapia delle forme avanzate con farmaci bersaglio. C è ancora spazio per l ablazione percutanea? Paestum 15 Maggio 2014 Prof A. Giorgio Director Interventional Ultrasound Units Athena
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationProfessor Norbert Bräu
Sixth Annual BHIVA Conference for the Management of HIV/Hepatitis Co-Infection in collaboration with BASL and BVHG Professor Norbert Bräu James J Peters VA Medical Center, New York, USA COMPETING INTEREST
More informationTACE: coming of age?
Invasive procedures in the diagnosis and treatment of liver diseases: focal lesions F.Farinati Gastroenterologia, Padova TACE: coming of age? AISF 2005 TACE: LEVELS OF EVIDENCE Degree of certainty Methodology
More informationHow to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung
How to evaluate tumor response? Yonsei University College of Medicine Kim, Beom Kyung End points in research for solid cancers Overall survival (OS) The most ideal one, but requires long follow-up duration
More informationHCC surgical approach: resection and transplantation indications and outcome
SAMO, Friday 15th April 2011 Workshop on Primary liver tumors HCC surgical approach: resection and transplantation indications and outcome Gilles Mentha University Hospital of Geneva Hepatocellular Carcinoma
More informationTrans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis?
Trans-arterial radioembolisation (TARE) of unresectable HCC using Y-90 microspheres: is it dangerous in case of portal vein thrombosis? Poster No.: C-1634 Congress: ECR 2014 Type: Authors: Keywords: DOI:
More informationAlpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer. Original Policy Date
MP 2.04.35 Alpha-Fetoprotein-L3 for Detection of Hepatocellular (Liver) Cancer Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationLife After SVR for Cirrhotic HCV
Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationMULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC
Dr Apoorva Gogna MBBS FRCR FAMS Consultant Interventional Radiology Center Department of Diagnostic Radiology SingaporeGeneral Hospital MULTI-DISCIPLINARY MANAGEMENT OF INTERMEDIATE STAGE HCC CASE HISTORY
More informationDespite recent advances in the care of patients with
Liver Transplantation for Hepatocellular Carcinoma: Lessons from the First Year Under the Model of End- Stage Liver Disease (MELD) Organ Allocation Policy Francis Y. Yao, 1,2 Nathan M. Bass, 1 Nancy L.
More informationNon-Invasive Testing for Liver Fibrosis
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Lanla F. Conteh MD, MPH Assistant Professor of Clinical Medicine Director, GHN Hepatobiliary Tumor Program Division of Gastroenterology, Hepatology and Nutrition The Ohio State
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Lanla F. Conteh MD, MPH Assistant Professor of Clinical Medicine Director, GHN Hepatobiliary Tumor Program Division of Gastroenterology, Hepatology and Nutrition The Ohio State
More informationHepatocellular Carcinoma in Qatar
Hepatocellular Carcinoma in Qatar K. I. Rasul 1, S. H. Al-Azawi 1, P. Chandra 2 1 NCCCR, 2 Medical Research Centre, Hamad Medical Corporation, Doha, Qatar Abstract Objective The main aim of this study
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationLiver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals
Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationHepatocellular carcinoma: Options for diagnosing and managing a deadly disease
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will recognize the risk of hepatocellular carcinoma in patients with cirrhosis, regardless of the cause of the cirrhosis ARVIND R. MURALI, MD Department
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1674-1679 Radioembolization in Treatment of Hepatocellular Carcinoma with Portal Vein Invasion Elsahhar Ahmed Hetta, Osama Mohamed
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationHepatocellular Carcinoma (HCC): Burden of Disease
Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More information